Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 3058105 | HLA IDENTICAL (HLA-IDENTICAL) | leukemia | NA | methotrexate | NA | unclassified | |
| the results of a prospective randomised trial comparing cyclosporin (csp) with methotrexate (mtx) as immunosuppressive therapy after hla-identical sibling marrow transplantation for patients with acute leukemia in first remission were analysed 2.5 years after entry of the last patient into the trial. | |||||||
| 3058233 | HLA IDENTICAL (HLA-IDENTICAL) | transplantation | NA | NA | NA | unclassified | |
| hla-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. | |||||||
| 3058233 | HLA IDENTICAL (HLA-IDENTICAL) | chronic myelogenous leukemia | NA | NA | NA | unclassified | |
| hla-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. | |||||||
| 3058233 | HLA IDENTICAL (HLA-IDENTICAL) | transplantation | NA | NA | NA | unclassified | |
| results of hla-identical allogeneic marrow transplantation were analyzed for 66 patients with accelerated-phase chronic myelogenous leukemia (cml). | |||||||
| 3058233 | HLA IDENTICAL (HLA-IDENTICAL) | chronic myelogenous leukemia | NA | NA | NA | unclassified | |
| results of hla-identical allogeneic marrow transplantation were analyzed for 66 patients with accelerated-phase chronic myelogenous leukemia (cml). | |||||||
| 3058801 | DP (HAPLOTYPE) | transplantation | NA | NA | NA | unclassified | |
| these data indicate the recognition of hla determinants in the course of an in vivo alloimmune response and particularly emphasize the role of hla-c and dp loci products so far ignored in clinical transplantation. | |||||||
| 3058801 | HLA-C (HLA-C) | transplantation | NA | NA | NA | unclassified | |
| these data indicate the recognition of hla determinants in the course of an in vivo alloimmune response and particularly emphasize the role of hla-c and dp loci products so far ignored in clinical transplantation. | |||||||
| 3075482 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| successful transplantation of kidneys bearing previously mismatched hla a and b locus antigens. | |||||||
| 3075482 | HLA (HLA) | transplantation | NA | NA | NA | unclassified | |
| transplantation of kidneys bearing hla antigens to which recipients have previously been exposed is generally avoided, and such prudence is a well-documented means of preventing early graft loss. | |||||||
| 3089939 | HLA MATCHED (HLA-MATCHED) | transplantation | NA | NA | NA | unclassified | |
| 122 patients with hematologic malignancies underwent allogeneic marrow transplantation from hla-matched sibling donors and received one of two forms of infection prophylaxis while granulocytopenic: 1) decontamination and laminar air flow isolation (laf, 68 patients), and 2) laf plus prophylactic systemic antibiotics (laf + psa, 54 patients). | |||||||
Copyright 2024